Skip Navigation


Brain Advance Access originally published online on December 2, 2006
Brain 2007 130(1):222-232; doi:10.1093/brain/awl332
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
130/1/222    most recent
awl332v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (6)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Huot, P.
Right arrow Articles by Parent, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Huot, P.
Right arrow Articles by Parent, A.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author (2006). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

The fate of striatal dopaminergic neurons in Parkinson's disease and Huntington's chorea

Philippe Huot1,2, Martin Lévesque1 and André Parent1

1 Centre de Recherche Université, Laval Robert-Giffard Québec, QC, Canada G1J 1Z4 2 Département des Sciences Neurologiques, CHAUQ-Hôpital de l'Enfant-Jésus Québec, QC, Canada G1J 1Z4

Corresponding author: André Parent, Centre de Recherche Université Laval Robert-Giffard, 2601, de la Canardière, Local F-6500, Québec, QC, Canada G1J 2G3 E-mail: andre.parent{at}anm.ulaval.ca

The striatum harbours a population of dopaminergic neurons that is thought to act as a local source of dopamine (DA). This neuronal population increases in size in animal models of Parkinson's disease, where striatal DA levels are low, but its fate in idiopathic Parkinson's disease and Huntington's chorea is poorly known. In this study, we used antibodies raised against the enzyme tyrosine hydroxylase (TH), a faithful marker of dopaminergic neurons, to compare, by means of stereological counting methods, the number of striatal TH+ neurons on post-mortem brain sections from Parkinson's disease patients, Huntington's disease patients and age-matched controls. Propidium iodide nuclear staining was also performed to avoid counting short TH+ axonal segments that bear a large swollen varicosity and resemble small bipolar neurons. In normal subjects, TH+ neurons were scattered throughout the striatum, but they abounded preferentially in the ventral portion of the structure and were more numerous in the putamen than in the caudate nucleus. They displayed a multipolar cell body of medium size (10–20 µm in diameter) that emitted 3–5 smooth dendrites, a typical characteristic of striatal interneurons. These TH+ cells were rarely found in the small TH-poor striosomes, most of them being embedded in the large TH-rich extrastriosomal matrix. The number of striatal TH+ neurons was also found to vary according to an inverse relation with the age of the subjects. In pathological brains, the morphological characteristics of the striatal TH+ neurons were relatively unaltered, but the number of such neurons was markedly reduced compared with controls. The striatum of Parkinson's disease patients was found to contain six times less TH+ neurons than that of controls, whereas the striatum of Huntington's disease patients was largely devoid of such neurons. These findings are at odds with the results obtained in rodent and monkey models of Parkinson's disease, in which the number of striatal TH+ neurons is reported to increase markedly following DA denervation. Since Parkinson's disease patients examined in this study were all treated with L-3,4-dihydroxyphenylalanine to compensate for the loss of striatal DA and that levels of striatal DA are reportedly higher in the striatum of Huntington's disease patients compared with controls, we hypothesize that local DA concentrations exert a negative feedback on the expression of TH phenotype by striatal interneurons. A better knowledge of factors governing the in vivo state of this ectopic neuronal population could open new therapeutic avenues for the treatment of Parkinson's disease and Huntington's chorea.

Key Words: basal ganglia; striatum; neurodegenerative diseases; dopamine; striatal neurons

Abbreviations: DA, dopamine; DAT, DA transporter; L-dopa, L-3,4-dihydroxyphenylalanine; SN, substantia nigra

Received June 24, 2006. Revised October 10, 2006. Accepted October 12, 2006.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
NeurologyHome page
J. Brotchie and C. Fitzer-Attas
Mechanisms compensating for dopamine loss in early Parkinson disease
Neurology, February 17, 2009; 72(7_Supplement_2): S32 - S38.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
S. J. Gold, C. V. Hoang, B. W. Potts, G. Porras, E. Pioli, K. W. Kim, A. Nadjar, C. Qin, G. J. LaHoste, Q. Li, et al.
RGS9 2 Negatively Modulates L-3,4-Dihydroxyphenylalanine-Induced Dyskinesia in Experimental Parkinson's Disease
J. Neurosci., December 26, 2007; 27(52): 14338 - 14348.
[Abstract] [Full Text] [PDF]


Home page
BrainHome page
W. San Sebastian, J. Guillen, M. Manrique, S. Belzunegui, E. Ciordia, A. Izal-Azcarate, P. Garrido-Gil, M. Vazquez-Claverie, and M. R. Luquin
Modification of the number and phenotype of striatal dopaminergic cells by carotid body graft
Brain, May 1, 2007; 130(5): 1306 - 1316.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.